Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes.

Reverse signaling of transmembrane TNF (mTNF) contributes to the versatility of this cytokine superfamily. Previously, we could demonstrate that mTNF acting as receptor confers resistance to bacterial lipopolysaccharide in monocytes and macrophages (MO/MPhi). Reverse signaling can be induced by incubation with the monoclonal anti-TNF antibody 195F and other TNF antagonists, such as the humanized monoclonal antibody infliximab and the humanized soluble TNF receptor construct etanercept, respectively, all in former or present clinical use. Here, we addressed the question whether there are differences in modulating the LPS response in MO/MPhi among these three antagonists. Whereas 195F and infliximab suppress both, the release of an LPS-induced endothelial cell apoptotic factor and proinflammatory cytokines, etanercept only protected against the LPS-triggered apoptosis activity, but left the LPS-induced cytokine release unchanged. These data could have clinical impact with regard to TNF neutralization strategies.

[1]  Volker Herzog,et al.  Establishment of a human cell line (mono mac 6) with characteristics of mature monocytes , 1988, International journal of cancer.

[2]  S. Ely,et al.  Engagement of CD153 (CD30 Ligand) by CD30+ T Cells Inhibits Class Switch DNA Recombination and Antibody Production in Human IgD+ IgM+ B Cells1 , 2000, The Journal of Immunology.

[3]  C. Smith,et al.  Reverse signaling via CD30 ligand. , 1996, Journal of immunology.

[4]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[5]  David Wallach,et al.  A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in ‘reverse signalling’ , 1999, The EMBO journal.

[6]  M. Feldmann,et al.  INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[7]  S. Nikolaus,et al.  Mechanisms in failure of infliximab for Crohn's disease , 2000, The Lancet.

[8]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[9]  F. Breedveld,et al.  Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.

[10]  L. Gooding,et al.  A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact , 1990, Cell.

[11]  Takahiko Horiuchi,et al.  Outside-to-Inside Signal Through the Membrane TNF-α Induces E-Selectin (CD62E) Expression on Activated Human CD4+ T Cells1 , 2001, The Journal of Immunology.

[12]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[14]  W. Fiers,et al.  Two tumour necrosis factor receptors: structure and function. , 1995, Trends in cell biology.

[15]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[16]  E. Holler,et al.  Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. , 1997, Blood.

[17]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.

[18]  C. Haslett,et al.  Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators , 1993, Journal of leukocyte biology.

[19]  A. Zinsmeister,et al.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.

[20]  W. Wilmanns,et al.  Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. , 1993, Transplantation proceedings.

[21]  J. Ferrara,et al.  The Pathophysiology of Acute Graft-versus-Host Disease , 2003, International journal of hematology.

[22]  Xiao-Yu Song,et al.  Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[23]  B. Scallon,et al.  Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.

[24]  T. Horiuchi,et al.  Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. , 2004, Gastroenterology.

[25]  P. Scheurich,et al.  A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. , 2001, Blood.

[26]  Pamela J. Fink,et al.  Maximal Proliferation of Cytotoxic T Lymphocytes Requires Reverse Signaling through Fas Ligand , 1998, The Journal of experimental medicine.

[27]  D. Gray,et al.  CD40 ligand-transduced co-stimulation of T cells in the development of helper function , 1995, Nature.

[28]  D. Hommes,et al.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.

[29]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[30]  Walter Kolch,et al.  Reverse Signaling Through Transmembrane TNF Confers Resistance to Lipopolysaccharide in Human Monocytes and Macrophages1 , 2000, The Journal of Immunology.

[31]  G. Ledderose,et al.  Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha , 1995, Blood.

[32]  A. Meager,et al.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. , 1988, Clinical and experimental immunology.

[33]  H. P. Fell,et al.  Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. , 1995, Immunity.

[34]  S. V. Deventer,et al.  Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease , 2001 .

[35]  D. Furst,et al.  Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.

[36]  W Domschke,et al.  Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.

[37]  A. Anis,et al.  Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease , 2003, The Annals of pharmacotherapy.

[38]  M. Ueffing,et al.  Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. , 1995, Blood.

[39]  N. Shen,et al.  Apoptosis and DNA fragmentation precede TNF‐induced cytolysis in U937 cells , 1992, Journal of cellular biochemistry.

[40]  J. Ghrayeb,et al.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. , 1993, Arthritis and rheumatism.

[41]  K. Schollmeier,et al.  Monoclonal antibodies to human tumor necrosis factor α: In vitro and in vivo application , 1990 .

[42]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[43]  C. Ferran,et al.  Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. , 1994, The Journal of clinical investigation.

[44]  R. Andreesen,et al.  CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. , 1998, Journal of immunology.

[45]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[46]  G. Tiegs,et al.  Chronic Inflammation and Protection from Acute Hepatitis in Transgenic Mice Expressing TNF in Endothelial Cells1 , 2001, The Journal of Immunology.

[47]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[48]  H. Schwarz,et al.  CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers , 2002, Journal of leukocyte biology.

[49]  R. Korngold,et al.  Role of tumor necrosis factor-α in graft-versus-host disease and graft-versus-leukemia responses , 2003 .

[50]  R. Soiffer,et al.  Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. , 2003, Blood.

[51]  H. Loetscher,et al.  Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram- negative sepsis , 1994, The Journal of experimental medicine.

[52]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[53]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[54]  Walter Kolch,et al.  LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway , 2004, Journal of leukocyte biology.

[55]  J. Boonstra,et al.  Antibody-induced dimerization activates the epidermal growth factor receptor tyrosine kinase. , 1991, The Journal of biological chemistry.